Project launch: Remote Assessment of Disease and Relapse – Alzheimer’s Disease

RADAR-AD will draw on a wealth of lessons and expertise from people active in the RADAR-CNS and other projects in developing remote measuring technology to be used by patients with early Alzheimer’s.

Like RADAR-CNS, RADAR-AD is a Public Private Partnership funded by the Innovative Medicines Initiative, with representation from academic institutions, small-to-medium enterprises, public organisations and pharmaceutical companies. Dag Aarsland from King’s College London is leading the project together with Vaibhav Narayan from Janssen Pharmaceutica. 

The team will seek solutions that take account of particular characteristics shared by many people with Alzheimer’s: many are older and may not have had much exposure to technology, and their condition may also make it more difficult for them to learn to handle technical devices. A key aim of the project is to find ways to measure any reduction in ability to live and function independently early on in the course of an individual’s condition.

Dag Aarsland commented: “There is more and more interest in the use of widely available and affordable digital technology to improve outcomes for people with Alzheimer’s. Our hope is that RADAR-AD will result in clinical and technological advancements so that valuable new treatments can be identified and implemented. People with Alzheimer’s Disease will be fundamentally involved in the design and development of the project so that the solutions we generate are acceptable and appropriate for people in their everyday lives.”